It must be admitted that in the pharmaceutical field, Chen Pingsheng is also an outsider.
His wife only started to focus on this field in recent years, investing roughly over a hundred billion in the big health sector.
It looks like a lot, but it's really just something like that.
As for becoming a giant in the pharmaceutical field, it's completely impossible.
Chen Pingsheng's own funds have not been tilted in this direction.
They annually calculate the economic growth rates of most developed countries worldwide.
And the development trends of core industries.
Additionally, there's relevant policies, competition, and so on.
The previous few overseas investments can only be considered as seeking steady progress, stabilizing first before development.
The greatest advantage of this model is stability; the disadvantage is that both the profit margin and assets require years to recoup the costs.
It is far less than the high risk, high return of venture capital.
